465 studies on Tirzepatide curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Independent certificate-of-analysis evidence from third-party labs — the data behind the studies. Updated as new COAs are verified.
| Manufacturer | Batches | Avg purity | |
|---|---|---|---|
| Bfflist Amo | 247 | 99.61% | View COA → |
| Sry Labs | 207 | 99.55% | View COA → |
| Shanghai Sigma Audley Ssa | 140 | 99.56% | View COA → |
| Hk Peptides | 127 | 99.76% | View COA → |
| Allen Biotechnology Co Abc | 124 | 99.66% | View COA → |
| GYC | 93 | 99.73% | View COA → |
| Zlz Peptide | 92 | 99.72% | View COA → |
| (unknown) | 74 | 99.7% | View COA → |
Recent certificates: #16760 (99.707%) · #16762 (99.853%) · #22208 (99.9%) · #22209 (99.9%) · #22296 (99.9%) · #22297 (99.8%)
Manufacturers with published third-party certificates of analysis for Tirzepatide. Open a vendor to see every batch we've verified.
This initial Phase 1/2 study of SRSD384 is crucial for understanding its foundational human profile. If successful, it could pave the way for a novel therapeutic agent for obesity and T2DM, potentially offering a new …
This review significantly expands the understanding of GLP-1 RAs beyond diabetes and obesity, establishing their utility in heart failure management, particularly for HFpEF/HFmrEF. For clinicians and biohackers, this …
Understanding the profound cardiometabolic consequences of discontinuing GLP-1RAs and tirzepatide is critical for clinicians and patients. Long-term adherence to these medications is paramount to sustain their benefit…
Data-mining analysis confirms GLP-1 receptor agonists, including semaglutide and tirzepatide, are associated with dose-dependent dysesthesia and burning skin sensations.
The exploration of GLP-1 receptor agonists for weight loss in end-stage heart failure patients awaiting heart transplantation carries profound implications for clinical practice and patient access to life-saving proce…
GLP-1 analogues could represent a novel, dual-benefit therapeutic option for patients with psoriasis who also contend with obesity or metabolic syndrome. This research suggests a new avenue for treatment, moving beyon…
If successful, the ARO-INHBE trial could introduce a novel therapeutic mechanism for obesity and type 2 diabetes mellitus (T2DM), potentially offering an alternative or complementary option to existing GLP-1 receptor …
A completed Phase 1 study characterized tirzepatide pharmacokinetics in 32 participants with normal to severe hepatic impairment after a single 5 mg SC dose.
This review provides crucial insights for peptide users and clinicians, clarifying why dual GLP-1R/GIPR agonists like tirzepatide offer superior weight loss and metabolic improvements over single GLP-1RAs like semaglu…
A 12-month observational study investigated tirzepatide, alone or with topical G21, for effects on cellulite severity and body composition in 92 participants.
Tirzepatide's real-world efficacy in improving sleep-disordered breathing offers a significant practical takeaway for clinicians and individuals managing obesity and type 2 diabetes. Beyond weight loss and glycemic co…
This case underscores the critical importance for clinicians to maintain a high index of suspicion for euglycemic ketoacidosis in patients using tirzepatide, even with normal blood glucose levels. The severe presentat…
Understanding patient and provider preferences for tirzepatide and CPAP in obesity and OSA is critical for optimizing treatment strategies and improving adherence. If patients show a strong preference for a pharmacolo…
This research significantly expands the potential therapeutic scope of Tirzepatide beyond its established roles in type 2 diabetes and obesity, suggesting a novel application in neurodegenerative diseases like Alzheim…
The findings from this cost-effectiveness analysis could profoundly impact treatment paradigms for HFpEF patients with obesity in Germany. If tirzepatide demonstrates superior cost-effectiveness, it could become a cor…
This analysis highlights a critical shift in the clinical research paradigm for GLP-1 agonists in obesity, moving beyond primary weight loss to encompass a wider spectrum of metabolic and organ-specific benefits. Clin…
This finding offers a promising new therapeutic avenue for managing Fabry disease, particularly for patients experiencing residual proteinuria despite current standard-of-care treatments. DUAL GIP/GLP-1Ra could signif…
Updated 2026 guidelines for obesity and type 2 diabetes mellitus emphasize the crucial role of modern GLP-1 analogues and tirzepatide in comprehensive management.
This research offers a crucial shift in the narrative around GLP-1RA discontinuation, suggesting that weight regain is not an inevitable outcome for all patients. For individuals considering or undergoing GLP-1RA ther…
This research suggests that DA5-CH could represent a significant advancement in the treatment of Parkinson's disease and other neurodegenerative disorders, potentially offering a more effective therapeutic strategy th…
This review underscores a paradigm shift in metabolic disease management, moving beyond single-target approaches to powerful multi-agonist strategies. For individuals managing T2DM, obesity, or MASLD, the emergence of…
The completion of this Phase 2 trial for tirzepatide in NASH is a significant step, as it could potentially introduce a much-needed therapeutic option for a disease with no approved pharmacological treatments. If posi…
This head-to-head Phase 3 trial is crucial for understanding the comparative efficacy and safety of Tirzepatide versus Semaglutide in Type 2 Diabetes patients already on metformin. The results will directly inform cli…
Understanding how tirzepatide impacts adipose tissue inflammation and fibrosis, even after metabolic improvements, is crucial for refining obesity treatment strategies. If adipose inflammation persists despite weight …
While specific results are not yet available, this study's design highlights the ongoing effort to precisely understand tirzepatide's mechanisms beyond just weight loss. Understanding if tirzepatide impacts energy exp…
This methodological study is crucial for advancing the confidence and utility of real-world data in clinical research. Understanding the reliability of claims data emulation for cardiovascular outcomes could significa…
This review underscores tirzepatide's potential to redefine the pharmacologic management of obesity-related OSAS, offering a systemic approach beyond traditional mechanical or surgical interventions. For peptide users…
This registry holds significant implications for understanding the pleiotropic effects of tirzepatide beyond its established metabolic benefits. For peptide users and clinicians, the data could illuminate whether tirz…
Understanding tirzepatide's safety and efficacy in transplant recipients is crucial for guiding clinical practice and improving outcomes in this high-risk population. Transplant patients require careful consideration …
This finding suggests a novel, direct mechanism by which GLP-1RAs could offer neuroprotection in Alzheimer's disease, moving beyond their established metabolic benefits. For individuals interested in neurodegenerative…
Given the high comorbidity of depression with diabetes and obesity, a compound like tirzepatide that addresses both metabolic and potential mood aspects could represent a significant therapeutic advancement. If future…
This Phase 1 study is a crucial step in the development of LY3841136 as a potential new therapy for obesity and overweight, especially given its investigation in combination with tirzepatide, a highly effective dual G…
If positive, this trial could represent a significant advancement in the treatment of obstructive sleep apnea, particularly for individuals with co-morbid obesity. Tirzepatide could offer a pharmacological alternative…
A randomized trial will compare semaglutide, tirzepatide, and metformin in 66 obese adults to assess their impact on genetic aging over 24 weeks.
If successful, this trial could establish tirzepatide as a novel therapeutic option for Long COVID, addressing a critical gap in treatment. The remote, decentralized design of the study is particularly significant, de…
This research highlights a novel, non-metabolic therapeutic potential for Tirzepatide in acute inflammatory conditions like acute lung injury (ALI). For clinicians and biohackers, this suggests that GLP-1/GIP agonism,…
Tirzepatide's SURMOUNT-MAINTAIN trial investigates the efficacy and safety of continued or reduced dosing for long-term weight maintenance in adults with obesity.
This network meta-analysis provides crucial insights for both clinicians and peptide users, emphasizing that renoprotection is not uniform across all GLP-1RAs and SGLT2is, particularly concerning acute kidney injury. …
This real-world study provides crucial validation that tirzepatide effectively promotes meaningful weight loss in both Type 2 Diabetes and non-diabetic obese adults, reinforcing its broad utility. The observed glycemi…
This discovery suggests HDM1005 could represent a significant advancement in treating metabolic disorders, potentially offering enhanced efficacy and a more convenient dosing schedule due to its extended half-life. Fo…
A Phase 3 real-world study will evaluate tirzepatide 15 mg weekly for weight management and safety in 440 overweight or obese adults.
This large-scale observational study is crucial for understanding the real-world comparative effectiveness of tirzepatide against other leading GLP-1RAs in preventing Major Cardiovascular Events in patients with Type …
This study will provide crucial real-world data on tirzepatide's safe and effective use for Type 2 Diabetes patients observing Ramadan. Currently, guidance for GLP-1 RAs and dual GIP/GLP-1 agonists during fasting peri…
This study's methodology establishes a crucial framework for comparing two significant obesity interventions—GLP-1 RAs and bariatric surgery—in the context of IBD management. For clinicians and patients navigating obe…
The development of GZR18 represents a significant step towards addressing the unmet need for more convenient and effective long-term weight management solutions. The potential for a less frequent dosing regimen (every…
This research provides compelling evidence for a novel mechanism by which Tirzepatide protects against cisplatin-induced AKI, specifically through its ability to restore NAD+ levels and enhance mitochondrial quality c…
These findings are highly significant as they suggest tirzepatide offers superior kidney protection compared to dulaglagutide, a widely used GLP-1 agonist, in patients with Type 2 Diabetes. Given that chronic kidney d…
This case report highlights a rare but severe adverse event associated with tirzepatide, suggesting that clinicians should be vigilant for interstitial nephritis in patients experiencing unexplained renal decline whil…
Incretin-based therapies represent a highly promising and multifaceted approach in hypertension management, uniquely combining significant metabolic and cardiovascular benefits. Their ability to reduce blood pressure,…
This study provides compelling real-world evidence that GLP-1 Receptor Agonist therapy offers substantial cardiorenal protection in Type 1 Diabetes patients, mirroring benefits previously observed in T2D. These findin…
Free, no account — handy when you're working with Tirzepatide.